Using the same threshold value at age 75, Gleason 7-9 (regardless of PSA) and Gleason 5-6 (with PSA >20) are cost effective. Hence, RP is not perceived to be cost effective in males aged 75 years having low Gleason and low PSA. Higher threshold values for patients with clinically localized prostate cancer could be discussed.
Introduction
The widespread use of prostate specific antigen (PSA) testing has led to a dramatic increase in detection of localized prostate cancer in most Western countries (1, 2) . Different treatment options are available to these patients in early stages. The most common option is radical prostatectomy (RP), but patients with newly diagnosed, localized, prostate cancer can also be managed in an expectative setting, but where clinicians expect to cure patients with radical surgery or radiotherapy if the tumor shows signs of progression. In recent years, active surveillance has become more common (3) . The lack of convincing scientific evidence on effectiveness still makes the choice of treatment strategy for localized prostate cancer controversial in many patient groups. A decision support model based on a decision analysis approach can offer helpful guidance in determining which treatment to choose for different patient groups (4) . Apart from appraising effectiveness in terms of survival, in most policymaking situations it is relevant to consider health-related quality of life (HRQoL) and cost effectiveness. A decision support model encompassing these factors should provide information for decision makers, providing them support in setting priorities when creating treatment guidelines. To handle uncertainty within the given parameters, a probabilistic sensitivity analysis is recommended (5) .
Some studies on localized prostate cancer have attempted to handle uncertainty by using a decision analytic approach, but with varying quality of data (6) (7) (8) . Although a randomized clinical trial (RCT) on the lifetime cost effectiveness of RP has never been reported, this type of assessment should be of substantial importance in developing an evidence-based policy for managing localized prostate cancer. The randomized trial, Scandinavian Prostatic Cancer Group Study Number 4, SPCG-4 (www.roc.se) compares watchful waiting (WW) with RP and investigates specific outcomes, e.g. survival, HRQoL, and costs. The results (presented in four papers) show that compared to watchful waiting, RP yields in gain in survival time for some patient groups, depending on the patient's age, Gleason score, and PSA value (9) (10) (11) (12) .
According to these reports, patients treated with RP have similar or higher HRQoL than patients treated with WW (13, 14) . Andersson et al studied the long-term cost of the two treatments and reported a lower cost for the WW group compared to the RP group (15) .
Slightly longer survival is gained at a higher cost. Probabilistic reasoning based on the data from these studies can be used to support decision makers in judging whether the extra cost per health-year gained is reasonable.
This study aims to develop a probabilistic decision support model to calculate the lifetime incremental cost-effectiveness ratio (ICER) between RP and WW. Since risk at baseline is a potentially important predictor of prostate cancer progression, the decision support model should also calculate the cost effectiveness for subgroups with different risk profiles. In this study, we combine survival, HRQoL, and cost data from the SPCG-4 trial (including full costeffectiveness analysis) to provide guidance concerning which treatment to use based on different patient characteristics.
Material and Methods
Our study uses a decision support method based on a semi-Markov model ( Figure 1 ) to handle all of the parameters and to extrapolate data for calculating lifetime mean costs and the number of quality-adjusted life-years (QALYs) per patient for the two treatment strategies.
We took a probabilistic approach to include uncertainty in the model. We calculated costs and number of QALYs for each year that a patient spends in each state in the semi-Markov model, allowing us to handle probabilities that vary with time spent in a specific state. A structured analysis model of prostate cancer interventions ( Figure 1 ) was first published in 1993 (16) .
We have modified the Markov model to use symptomatic disease instead of hormonally controlled metastasis and to use refractory disease instead of refractory metastasis. An
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assumption in the model is that patients cannot die of prostate cancer unless they have developed a refractory disease.
The analysis takes the perspective of the Swedish healthcare system, and costs are The transition probabilities (risks) of moving from localized prostate cancer to symptomatic disease, from symptomatic disease to refractory disease, and from refractory disease to death in prostate cancer were taken from individual-patient data from SPCG-4.
Costs and health-related quality of life were also estimated from individual-patient data from SPCG-4, but costs were based on a subsample of SPCG-4. The probability of dying from causes other than prostate cancer was estimated from Swedish standard life-tables.
Data sources
We used data from the 695 patients enrolled in SPCG-4 between October 1989 and February 1999 (9) (10) (11) . Eligible patients were aged <75 years, life expectancy was >10 years, and no other malignancy was present. Tumors had to be newly diagnosed and localized to the prostate, and the PSA value had to be <50 ng/mL. The patients were randomized to either early surgery (RP) or a conservative strategy (WW). The surgery started with pelvic lymphadenectomy, and if the histopathology evaluations of the removed lymph nodes were negative, RP was performed. In the WW group, no immediate treatment was performed, but transurethral resection was first-line treatment for symptom relief due to infravesical obstructions.
Transition probabilities (risks)
All statistical analyses included previously identified baseline risk factors for prostate cancer progression and randomized treatment as separate covariates, namely Gleason (2-4, 5-6, 7, 8-9, missing), PSA (<4ng/mL, 4-6.9 ng/mL, 7-10ng/mL, 10.1-20ng/mL, >20ng/mL or missing), age, and treatment (RP, WW) (11).
The general approach involves testing all covariates with both an exponential distribution and a Weibull distribution, where the exponential distribution handles risk as constant while the Weibull distribution is used when the risk is time-dependent (17). Log-likelihood ratio tests (18) were used to find the distribution that best fit the dataset and to select which explanatory variables to use. By using this method, some of the explanatory variables in the estimation of event rates were retained regardless of statistical significance ( Figure 1 ). A covariance matrix was calculated between the parameters, and Cholesky decomposition (19) was used to account for dependence between parameters.
In Figure The mortality risk from other causes was estimated using Swedish age-specific life-tables for men, adjusted to exclude prostate-cancer-specific mortality (www.scb.se).
Costs
Data related to the resources used for prostate cancer were collected retrospectively in SPCG-4 by reading up to 17 years of patient records, as reported in detail elsewhere (15) .
We used generalized linear model (GLM) to estimate the annual mean cost per state (20) .
The GLM method was used with Gamma distribution and a Log-link to obtain the best cost for each disease state (Figure 1 ). Before implementing the GLM, replicated observations were used to estimate the mean cost per patient and year. The Akaikes Information Criterion (AIC) was used in choosing which explanatory variables to include in the analysis (21) . Again, Cholesky decomposition was used in accounting for dependence between variables.
Health-related quality of life
Health-related quality-of-life (HRQoL) data were collected for Swedish patients who were still alive on several occasions in the SPCG-4 study when a 77-item questionnaire with a visual analogue scale (VAS) was used to measure HRQoL. The patients estimated their HRQoL at several times and in different disease states. Replicate observations per patient were used when calculating the HRQoL estimates for the three disease states in the model.
To estimate QALYs for each treatment strategy, the patients' time in each health state was multiplied by quality-adjustment weights (utilities) on a scale where 0 represents death and 1 represents full health (taken from the VAS score). We used a two-step procedure to obtain the mean values for the three different health states and to stratify treatment values. First an individual mean value is calculated for each patient for a specific state and treatment. Then a state-and treatment-specific mean value is calculated based on the individual mean values.
All data were analyzed using PASW Statistics 18.
Cost effectiveness
The incremental cost-effectiveness ratio (ICER) is used to measure cost effectiveness.
Cost-effectiveness measures the additional sum one must pay to gain an extra QALY, i.e. one year with full health, and is calculated by dividing the difference in mean cost by the mean QALY between the two treatment strategies. We used age, Gleason score, and PSA value in stratification since these are the most important factors in estimating the ICER.
Results
The decision support model developed in this study is based on the reasoning that resulted from probabilistic calculations of data from SPCG-4. Costs and QALYs are calculated from each disease state (Figure 1 ) for the two different treatment strategies. These measures are then summarized and discounted, and the mean values are calculated from each probabilistic simulation to obtain the cost-effectiveness value. Table I shows the difference in cost between the two strategies, the difference in QALY, and the cost-effectiveness ratio or ICER. Also presented is the probability that RP is cost At 80 years of age (not shown in Table I ) most of the ICERs exceed 500 000 SEK, with the exception of Gleason 7-9 and PSA >10, which generate ICERs below 500 000 SEK (range 248 210 SEK to 448 451 SEK). The reason for high ICER values at 80 years of age and above is that the remaining life expectancy is short, and the potential benefits of RP are not fully achieved.
Cost effectiveness
The probability of RP being cost effective at certain values is 100% regardless of Gleason, even at the low value of 100 000 SEK at 55 to 60 years of age (not shown in Table I ). The probability at age 70 and Gleason 0-4, and at age 75 and Gleason 8-9, is similar at a threshold value of 200 000 SEK. Figure 2 presents an example of decision support implementation using probabilistic sensitivity analysis based on calculations using equations 1 to 3 in Figure 1 . In steps 1 to 3, the characteristics (i.e. age, Gleason score, and PSA value) of the patient group of interest can be entered. The program then runs the probabilistic reasoning module to calculate the cost and the QALY based on survival and HRQoL data for RP and WW. The cost column shows the costs of the two treatment strategies and the difference between them. The QALY column shows the QALY generated by the two strategies and the difference between them. The last result shown is the ICER, where the cost of gaining a QALY is calculated for RP versus WW.
In this example, the RP strategy costs an additional 46 043 SEK, but generates 1.14 QALY more than the WW strategy. Hence, the ICER is (46 043 / 1.14) = 40 444 SEK. Decision makers can use this information to support judgments on whether or not a specific patient group should be treated with RP, their threshold values, and other priority setting.
Step 
Discussion
Decision analysis
Cost-effectiveness ratios of combinations of interventions and defined patient groups, together with defined threshold values, could be used in making policy decisions (22) . Is RP cost effective in relation to WW, and should the procedure be recommended for routine use?
Sweden has not defined the thresholds of cost effectiveness for different health conditions.
Rather, severity and other relevant aspects are considered in determining when a treatment option should be recommended for routine use in health services. The National Institute for
Health and Clinical Excellence in the UK uses a threshold of around 20 000 to 30 000 pounds sterling (GBP) per QALY gained. Therefore, we have developed a decision support model and calculated the probability of RP being cost effective at several cut-off values of the ICER, i.e. levels of willingness-to-pay for health (Table I, Figure 2 ).
We evaluated uncertainty in cost effectiveness by using probabilistic sensitivity analysis where inputs into the analysis are defined as probability distributions reflecting the precision with which they are estimated (23) . To illustrate the variability in costs and QALYs, we estimated the cost effectiveness of RP by using data from different patient groups. These groups are based on different ages, Gleason and PSA values since these are the best prognostic factors concerning prostate cancer mortality. Heredity and unhealthy lifestyle are other possible risk factors for mortality in prostate cancer patients. For more precise estimates, the PSA ratio could also be a good complement to PSA. Unfortunately, these data were not collected in the SPCG-4 trial, but may be considered in future versions of the model.
Decision makers can use the results as a base when constructing treatment guidelines for patient groups with localized prostate cancer. However, they should use their priorities and
ICER threshold values as a basis for determining which groups are cost effective. The major strength of this analysis compared to earlier model analyses is that the data come from a randomized trial, presumably excluding selection bias. The long-term follow-up also strengthens the result. Long-term follow-up enhances data credibility since it enables researchers to identify long-term treatment effects. The study includes actual resource-use data, i.e. the cost data are not based on hypothetical assumptions as is often the case in other similar studies.
A limitation of the analytic method presented here is that it simulates from study data and extrapolates data to a lifetime horizon, instead of following up the patients until they die. The problem with the latter approach is that it is expensive and takes many years. Moreover, clinical guidelines and treatment methods could change during a prolonged follow-up period.
This study has a long-term median follow-up of 10 to 12 years, and we have little reason to believe that a dramatic change in the data would occur after this period. A limitation concerning Gleason could affect the results of this study; specifically, the SPCG-4 included only patients with localized prostate cancer in curable ages (<=75 years), which leads to underrepresentation of Gleason 8-10.
Even if the data present good internal validity, their external validity could be discussed, e.g. perhaps the result is not fully applicable in different clinical contexts relative to the period of data collection. The first patient was enrolled in 1989, and treatment methods have improved since then. Moreover, new treatment modalities, e.g. robotic surgery, have been introduced and are now commonly used. However, this procedure is more expensive than RP, and its treatment effects compared to RP have not been fully investigated. Due to widespread PSA screening, more indolent tumors are being diagnosed, and concomitant overtreatment has become a major clinical and ethical dilemma. Active surveillance is increasingly used to counteract the problem of overtreatment. This may be taken into consideration in the decision-making process regarding treatments. The decision support model should be updated with active surveillance data when long-term data from randomized trials becomes available.
Conclusions
The cost-effectiveness ratio for RP varies with age, Gleason score, and PSA values.
Assuming a threshold value of 200 000 SEK per QALY gained, in patients aged <=70 years the treatment is always cost effective, except at age 70, Gleason 0-4, and PSA <=10. Using the same threshold value at age 75, Gleason 7-9 (regardless of PSA) and Gleason 5-6 (with PSA >20) are cost effective. Hence, RP is not perceived to be cost effective in males aged 75 years having low Gleason and low PSA. Higher threshold values for patients with clinically localized prostate cancer could be discussed.
